These patients were participants in the double-blind , placebo-controlled randomized OmegAD study in which 204 patients with mild Alzheimer 's disease ( AD ) received 2.3 g n-3 FA [ high in docosahexaenoic acid ( DHA ) ] or placebo daily for 6 months .